Scientific conclusions and grounds for the variation to the 
terms of the marketing authorisation(s) 
Active substance(s): belantamab mafodotin 
Procedure No. EMEA/H/C/PSUSA/00010869/202208 
30 March 2023 
EMA/264790/2023 
Committee for Medicinal Products for Human Use (CHMP) 
Medicinal product no longer authorised
Period covered by the PSUR: 5 February 2022 – 4 August 2022 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
 
 
 
Scientific conclusions 
Taking into account the PRAC Assessment Report on the PSUR(s) for belantamab mafodotin, the 
scientific conclusions of CHMP are as follows:  
accordingly. 
In view of available data on changes in the subbasal nerve plexus of cornea and decreased sensitivity of 
to the proposed changes to the product information 
The CHMP agrees with the scientific conclusions made by the PRAC. 
Grounds for the variation to the terms of the marketing authorisation(s) 
The CHMP recommends that the terms of the marketing authorisation(s) should be varied. 
that the product information of products containing belantamab mafodotin should be amended 
On the basis of the scientific conclusions for belantamab mafodotin the CHMP is of the opinion that the 
benefit-risk balance of the medicinal product(s) containing belantamab mafodotin is unchanged subject 
cornea from the literature, spontaneous reports including evident temporal and dose relationship, a 
positive de-challenge and in view of a plausible mechanism of action, the PRAC Rapporteur considers a 
causal relationship between belantamab mafodotin and changes in the subbasal nerve plexus of cornea 
and decreased sensitivity of cornea is at least a reasonable possibility. The PRAC Rapporteur concluded 
Medicinal product no longer authorised
Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)  
EMA/264790/2023 
Page 2/2 
 
 
 
 
